An Open-label, Randomized, Single Dose, Two-way Crossover Study to Determine the Bioavailability of One Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of One Dutasteride 0.5 mg Capsule and One Tamsulosin Hydrochloride 0.2 mg Tablet in Healthy Male Subjects in the Fed and Fasted States

Next Previous
Trial Profile

An Open-label, Randomized, Single Dose, Two-way Crossover Study to Determine the Bioavailability of One Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of One Dutasteride 0.5 mg Capsule and One Tamsulosin Hydrochloride 0.2 mg Tablet in Healthy Male Subjects in the Fed and Fasted States

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Dutasteride/tamsulosin (Primary) ; Dutasteride; Tamsulosin
  • Indications Benign prostatic hyperplasia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 13 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 29 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top